| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 24003 |
| Drug | Tirzepatide |
| Brand | Mounjaro® |
| Indication | Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
| Assessment Process | |
| Rapid review commissioned | 24/01/2024 |
| Rapid review completed | 06/02/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tirzepatide compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/03/2024 |
